Here are four takeaways:
1. Mr. Hannon was appointed CEO of Mainstay Medical on Sept. 5 2017. Mr. Hannon took up his role as CEO on Oct. 9, 2017.
2. Previously, Mr. Hannon serves as president and CEO of NuVasive. During his tenure, NuVasive’s commercial presence expanded globally to more than 40 countries and grew revenues to $962 million.
3. Currently, Mainstay Medical is focusing on the development and commercialization of ReActiv8, an implantable restorative neurostimulation system to treat chronic low back pain.
4. ReActiv8 has begun a global clinical trial for future FDA approval. Mr. Hannon will work to expand the device globally and continue to build its platform.
More articles on devices and implants:
DePuy Synthes, Stryker, Zimmer Biomet & more: 13 device company notes
OMNIlife science exceeds 17k total knee replacements using OMNIBotics: 5 notes
Balloon kyphoplasty segment leads vertebral compression fracture devices market: 7 observations
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
